 Shares of Five Prime Therapeutics Inc. blasted 314 higher in premarket trading Wednesday, after the company said its treatment for gastric cancer met all three of its efficacy endpoints from Phase 2 trial. The rally put the stock on track to open at the highest level seen during regular-session hours since February 2018. 